Anavex Life Sciences Corp.
AVXLAnavex Life Sciences is a clinical-stage biopharmaceutical company that utilizes precision medicine and genomic data to develop therapeutics for central nervous system (CNS) diseases.
Earnings
Next report
Nov 24, 2026 (in 2 months)Competitors
By market cap
By revenue growth
Profile
Anavex Life Sciences is a clinical-stage biopharmaceutical company that utilizes precision medicine and genomic data to develop therapeutics for central nervous system (CNS) diseases. The company's core strategy involves targeting the sigma-1 receptor (SIGMAR1) to restore cellular homeostasis and treat neurodegenerative and neurodevelopmental disorders. Its lead drug candidates are designed to address high unmet needs in conditions such as Alzheimer’s disease, Parkinson’s disease, and Rett syndrome.
A clinical-stage developer utilizing a unique SIGMAR1 activation platform and precision medicine biomarkers to differentiate its CNS pipeline from traditional symptomatic treatments.
FAQ
- What is Anavex Life Sciences Corp.'s market cap?
- Anavex Life Sciences Corp. (AVXL) has a market capitalization of $218.8M and trades on NASDAQ.
- Who are Anavex Life Sciences Corp.'s competitors?
- Anavex Life Sciences Corp.'s key competitors include Biogen, Eli Lilly and Company, Acadia Pharmaceuticals, and others. These companies compete in similar markets and product categories.
- Who does Anavex Life Sciences Corp. partner with?
- Anavex Life Sciences Corp.'s notable partners include The Michael J. Fox Foundation, International Rett Syndrome Foundation, Stanford University, and others.
- Where is Anavex Life Sciences Corp. headquartered?
- Anavex Life Sciences Corp. is headquartered in United States of America and employs approximately 40 people. It has been publicly traded since 2006.